Online Adaptive Radiotherapy for Cervical Cancer

Inclusion criteria

• 18-80 years old;
• Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma;
• 2018 FIGO Stage Ib3, II, IIIB and IIIC1
• Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses)
• ECOG score 0-2
• Life expectancy greater than 6 months
• Ability to remain lying down for more than 30 minutes
• Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form
• Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine <1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal
• Must complete baseline assessments and investigations required before treatment before enrolment
• be eligible for regular follow-up

Exclusion criteria

• Have received radiotherapy or chemotherapy in the past
• Have undergone radical surgery for cervical cancer
• Have a previous history of malignant tumor
• Pregnant or lactating women
• Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases.